CBCarmela Baviello

Carmela Baviello

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carmela Baviello has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CCDC6 immunostaining in conjunction with the Rad51 HRD assay may expand PARPi treatment eligibility in HGSOC patients.

    by Daniela Criscuolo, Francesco Merolla, Benedetta Pellegrino, Luca Russolillo, Ilaria De Benedictis, Daniela Califano, Rosaria Catalano, Carmela Baviello, Silvia Varricchio, Sabrina C Cecere, et al.

    HGSOC patients with BRCA1/2 mutations show HRD and PARPi sensitivity. Notably, HRD and PARPi response can occur without BRCA mutations, suggesting other factors are involved. Loss of CCDC6 function can lead to HRD and PARPi sensitivity in HGSOC cells, making CCDC6 a potential therapeutic target and biomarker. Three CCDC6 missense mutations in HGSOC prompted investigation into their impact on HRD. Analyzing CCDC6 expression, localization and HRD data in the MITO16A trial aims to clarify the CCDC6-HRD relationship in a large cohort. The biochemical and morphological effects of CCDC6 mutants on the native protein were examined using pull-down assays and immunofluorescence. HR-reporter and cell viability assays determined the impact of these mutants on HRD and PARPi sensitivity. CCDC6 histochemical score and intracellular-localization were assessed in MITO16A samples after immunostaining and digitalization. CCDC6-mutated isoforms act as dominant-negative, preventing native CCDC6 nuclear translocation, disrupting RAD51 foci and HR-repair, and increasing PARPi sensitivity. In the MITO16A patient sample set, 66 of 185 (35%) showed barely detectable CCDC6 or nuclear exclusion ("CCDC6-inactive"). CCDC6 impairment in these "CCDC6-inactive" samples was associated with HRD in 75% (30/40) of suitable samples analyzed by the RAD51 test and in 52% (34/65) of suitable samples analyzed by genomic HRD testing, even in the presence of wild-type BRCA1/BRCA2 genes. The association between CCDC6 inactivity and HRD, both at genomic and functional level, occurred even in presence of wild-type BRCA1/BRCA2 genes, suggesting that CCDC6 may play a crucial role in DNA repair pathways independent of these well-known genes.


  • Open Access

    Artificial Intelligence and Digital Pathology: Technological Transformation and Strategic Impact in Clinical Research and Medical Affairs

    by Carmela Baviello, Daniela Maria Capuano, Roberto Verna

    The progressive integration of Whole Slide Imaging (WSI) technology and Artificial Intelligence (AI) architectures is driving a structural transformation in pathology and precision oncology. This structured critical review analyzes and systematizes the impact of this technological transition along two fundamental operational dimensions of the modern biopharmaceutical industry: pre-registration Clinical Research and post-launch strategies governed by Medical Affairs. The first section explores how computational pathology is improving efficiency and reducing risk in drug development. Replacing analog visual assessment—intrinsically subject to inter-observer and intra-observer variability—with quantitative algorithms for cellular classification and segmentation enables optimization of patient recruitment in clinical trials, reducing screening failure rates. This review also examines the emerging role of Spatial Biology in extracting complex topological metrics from the Tumor Microenvironment (TME) and the use of AI for the objective and auditable quantification of critical surrogate endpoints, such as Pathological Complete Response (pCR), while acknowledging that algorithmic precision remains sensitive to pre-analytical variables and dataset biases. In the second section, the study investigates the strategic evolution of Medical Affairs, acting as a vital scientific communication and translational bridge between the complexity of Data Science and clinical hospital practice. Challenges related to AI adoption by clinicians are examined, emphasizing the importance of educational programs based on Explainable AI (XAI) to overcome the cognitive limitations of the black-box paradigm and the complex regulatory validation pathway for Software as a Medical Device (SaMD) under the stringent European IVDR framework—supported by an analysis of historical regulatory benchmarks such as the Paige Prostate case. The paper also explores the potential of AI in the large-scale generation of Real-World Evidence (RWE), applied to the creation of synthetic control arms in pharmacoeconomic settings. In conclusion, the study highlights that the diagnostic algorithm has ceased to be merely a laboratory support tool and has become a strategic asset and an integral adjunct to therapeutic decision-making. Overcoming current challenges related to data privacy through Federated Learning architectures, together with the imminent transition toward Foundation Models, foreshadows a fully data-driven healthcare ecosystem, making continuous skills development (digital upskilling) an essential requirement for professionals in the biopharmaceutical sector.

  • Open Access

    KRAS-Mediated CCDC6 Degradation Drives xCT Upregulation and Ferroptosis Evasion

    by Daniela Criscuolo, Rosaria Catalano, Carmela Baviello, Claudia Fioravanti, Elena Vigliar, Francesco Morra, Maria Marotta, Junsei Mimura, Antonino Iaccarino, Francesco Pepe, et al.

    Oncogenic KRAS mutations drive tumorigenesis by promoting pro-survival signaling and metabolic reprogramming, including the maintenance of redox balance to evade oxidative stress. A key mechanism involves the upregulation of the xCT cystine/glutamate antiporter, which sustains glutathione (GSH) synthesis and protects cells from oxidative damage and ferroptosis. While it is known that the ETS1-ATF4 complex mediates transcriptional upregulation of xCT, the upstream regulators linking KRAS signaling to this axis remain to be fully defined. Here, we demonstrate that oncogenic KRAS signaling induces the GSK3β-mediated proteasomal degradation of the tumor suppressor CCDC6. We show that CCDC6 acts as a negative regulator of the xCT-promoting transcription factor ATF4 by directly interacting with it and preventing its recruitment to the xCT promoter. Consequently, KRAS-driven CCDC6 degradation disinhibits ATF4, leading to increased xCT expression, elevated intracellular GSH, and enhanced resistance to ferroptosis. Crucially, pharmacological inhibition of CCDC6 turnover using proteasome, GSK3β, or specific KRAS mutant inhibitors (Sotorasib, Adagrasib, HRS4642) restored CCDC6 protein levels and robustly sensitized KRAS-mutated cells to ferroptosis-inducing agents like Sulfasalazine. Furthermore, validation in preclinical models and human colorectal cancer samples revealed that CCDC6 protein levels are predominantly downregulated in KRAS-mutant cases This work uncovers a novel KRAS/CCDC6/xCT signaling axis that mediates ferroptosis resistance in KRAS-mutated cancers. Moreover, it identifies CCDC6 turnover as a critical vulnerability and a promising therapeutic target to enhance the efficacy of ferroptosis-inducing agents.

  • Open Access

    Figure S1 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

    by Daniela Criscuolo, Francesco Merolla, Benedetta Pellegrino, Luca Russolillo, Ilaria De Benedictis, Daniela Califano, Rosaria Catalano, Carmela Baviello, Silvia Varricchio, Sabrina C. Cecere, et al.

    Figure S1. Summary statistics of H-scores for protein localization categories.

  • Open Access

    Figure 3 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

    by Daniela Criscuolo, Francesco Merolla, Benedetta Pellegrino, Luca Russolillo, Ilaria De Benedictis, Daniela Califano, Rosaria Catalano, Carmela Baviello, Silvia Varricchio, Sabrina C. Cecere, et al.

    Mutated isoforms of CCDC6 sensitize HGSOC cells to the PARPi olaparib alone or in combination with cisplatin. A–D, Drug sensitivity to olaparib or cisplatin has been evaluated by cell viability assay (CellTiter 96 Aqueous One Solution assay, Promega) in OVCAR3 and OV90 cell lines transfected with the myc-CCDC6 mutated isoforms L217P, A226S, and P442S or with the EV and exposed to the drug for 144 hours. The drug sensitivity is expressed as IC50 values. Statistical significance was verified by two-way ANOVA (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). E, The CI values according to the 1:2 concentration ratio of cisplatin and olaparib are shown (CI < 1, CI = 1, and CI > 1 indicate synergism, additive effect, and antagonism, respectively).

  • Open Access

    Figure S2 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

    by Daniela Criscuolo, Francesco Merolla, Benedetta Pellegrino, Luca Russolillo, Ilaria De Benedictis, Daniela Califano, Rosaria Catalano, Carmela Baviello, Silvia Varricchio, Sabrina C. Cecere, et al.

    Figure S2. IHC analysis of CCDC6 staining intensity and localization; CCDC6 expression evaluated by IHC compared to negative IgG control.

  • Open Access

    Figure S3 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

    by Daniela Criscuolo, Francesco Merolla, Benedetta Pellegrino, Luca Russolillo, Ilaria De Benedictis, Daniela Califano, Rosaria Catalano, Carmela Baviello, Silvia Varricchio, Sabrina C. Cecere, et al.

    Figure S3: (A) Immunofluorescence shows yH2AX nuclear foci formation in OVCAR3/OV90 cells after transfection with myc- CCDC6 mutated isoforms (A226S, L2 l 7P, P442S) or Empty Vector (EV) control and treatment with Etoposide [10 µM] for 8 hours. (B) Graphs display the percentage of cells with >5 foci (±SEM). (C-D) Western blots detect RAD5 l protein levels following transfection with CCDC6 mutated isoforms (C) or stable CCDC6 silencing (D) in OVCAR3/OV90 cells. Anti- Myc/Anti-CCDC6 and Anti-Tubulin were used as transfection/depletion and loading controls, respectively. (E-F) OVCAR3/OV90 cells, transfected with Myc-CCDC6 mutated isoforms/EV plus DR-GFP construct and I-Seel enzyme, were assessed for Homology-Directed Repair (HDR) efficiency (percentage of GFP positive cells, ±SEM).

  • Open Access

    Figure S5 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

    by Daniela Criscuolo, Francesco Merolla, Benedetta Pellegrino, Luca Russolillo, Ilaria De Benedictis, Daniela Califano, Rosaria Catalano, Carmela Baviello, Silvia Varricchio, Sabrina C. Cecere, et al.

    Figure S5: Immunofluorescence images of OVCAR3 cells stably silenced for CCDC6 (shCCDC6) or control cells (shCTRL) transfected with the GFP vector (a-d) or the GFP-CCDC6 wild type (WT) co-transfected with the myc-tagged CCDC6 wild type (i-1), the mutated isoforms A226S, L217P and P442S expression vectors (m-x) or the empty vector (EV) as control (e-h). Nuclei are stained with Hoechst (Blue-channel). GFP-CCDC6 WT protein is shown in the green channel. The myc-tagged CCDC6 WT and mutated isoforms were visualized by the anti-myc antibody (red-channel).

  • Open Access

    Figure S4 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

    by Daniela Criscuolo, Francesco Merolla, Benedetta Pellegrino, Luca Russolillo, Ilaria De Benedictis, Daniela Califano, Rosaria Catalano, Carmela Baviello, Silvia Varricchio, Sabrina C. Cecere, et al.

    Figure S4: (A) Levels of endogenous CCDC6, MycCCDC6 WT and mutated isoforms overexpression were assessed in OVCAR3 and OV90 cells by Western Blot using an anti-CCDC6 antibody. Tubulin is shown as loading control. (B) Levels ofMyc-CCDC6 WT and mutated isoforms overexpression and the degree of CCDC6 silencing were assessed in OVCAR3 and OV90 cells by Western Blot using an anti-CCDC6 antibody. Tubulin is shown as loading control. (C-D) Following treatment with Etoposide [10 µM] for 8 hours, cell viability was assessed in OVCAR3 and OV90 cells (C) as well as in OVCAR3 and OV90 cells stably silenced for CCDC6 (shCCDC6) (D) transfected with the myc-tagged CCDC6 wild type (WT), the mutated isoforms, A226S, L2l 7P and P442S expression vectors, or the empty vector (EV). Error bars indicate the standard error mean derived from three independent experiments.

  • Open Access

    Figure 4 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

    by Daniela Criscuolo, Francesco Merolla, Benedetta Pellegrino, Luca Russolillo, Ilaria De Benedictis, Daniela Califano, Rosaria Catalano, Carmela Baviello, Silvia Varricchio, Sabrina C. Cecere, et al.

    CCDC6 inactivation correlates with an HRD phenotype in patients with HGSOC. A, Representative images of IHC analysis of CCDC6 expression (a–c) and localization (d–f) in FFPE MITO16A patient samples (magnification 40×). The H-score values are listed as follows: a, (9); b, (50.68); c, (138.86); d, (149.61); e, (194.51); and f, (262.82). B, Summary of the MITO16A cases with CCDC6 inactivation, assessed for HRD test and/or RAD51 test and/or BRCA1/2 status. C, Causes of failure for the RAD51 assay in CCDC6 inactive samples. D, Percentages of Homologous Recombination Proficiency (HRP) and HRD tumors assessed by functional HRD testing among CCDC6 inactive MITO16A samples. E, Percentages of non-HRD and HRD tumors assessed by genomic HRD testing among CCDC6 inactive MITO16A samples. F, Percentage of BRCA1 and BRCA2 WT or mutated tumors among CCDC6-inactive MITO16A samples.